Education
About Us
Working with TipRanks
Follow Us
Iovance Biotherapeutics Inc (DE:2LB)
FRANKFURT:2LB
Total Valuation
Iovance Biotherapeutics has a market cap or net worth of €1.33B. The enterprise value is €1.14B.
Market Cap€1.33B
Enterprise Value€1.14B
Share Statistics
Iovance Biotherapeutics has 411,961,600 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding411,961,600
Owned by Insiders0.31%
Owned by Institutions18.82%
Financial Efficiency
Iovance Biotherapeutics’s return on equity (ROE) is -0.56 and return on invested capital (ROIC) is -51.52%.
Return on Equity (ROE)-0.56
Return on Assets (ROA)-0.43
Return on Invested Capital (ROIC)-51.52%
Return on Capital Employed (ROCE)-0.52
Revenue Per Employee314.44K
Profits Per Employee-466.56K
Employee Count838
Asset Turnover0.29
Inventory Turnover0.14
Valuation Ratios
The current PE Ratio of Iovance Biotherapeutics is ―. Iovance Biotherapeutics’s PEG ratio is 0.17.
PE Ratio―
PS Ratio3.70
PB Ratio1.40
Price to Fair Value1.40
Price to FCF-2.90
Price to Operating Cash Flow-5.04
PEG Ratio0.17
Income Statement
In the last 12 months, Iovance Biotherapeutics had revenue of 263.50M and earned -390.98M in profits. Earnings per share was -1.09.
Revenue263.50M
Gross Profit256.22M
Operating Income-403.36M
Pretax Income-393.05M
Net Income-390.98M
EBITDA-357.11M
Earnings Per Share (EPS)-1.09
Cash Flow
In the last 12 months, operating cash flow was -302.41M and capital expenditures -33.84M, giving a free cash flow of -336.24M billion.
Operating Cash Flow-302.41M
Free Cash Flow-336.24M
Free Cash Flow per Share-0.82
Dividends & Yields
Iovance Biotherapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.20
52-Week Price Change-11.23%
50-Day Moving Average2.28
200-Day Moving Average2.01
Relative Strength Index (RSI)74.65
Average Volume (3m)2.45K
Important Dates
Iovance Biotherapeutics upcoming earnings date is May 7, 2026, TBA (Confirmed).
Last Earnings DateFeb 24, 2026
Next Earnings DateMay 7, 2026
Ex-Dividend Date―
Financial Position
Iovance Biotherapeutics as a current ratio of 3.20, with Debt / Equity ratio of 6.93%
Current Ratio3.20
Quick Ratio2.83
Debt to Market Cap0.05
Net Debt to EBITDA0.32
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Iovance Biotherapeutics has paid -2.07M in taxes.
Income Tax-2.07M
Effective Tax Rate<0.01
Enterprise Valuation
Iovance Biotherapeutics EV to EBITDA ratio is -2.41, with an EV/FCF ratio of -2.56.
EV to Sales3.27
EV to EBITDA-2.41
EV to Free Cash Flow-2.56
EV to Operating Cash Flow-2.85
Balance Sheet
Iovance Biotherapeutics has €296.98M in cash and marketable securities with €48.44M in debt, giving a net cash position of €248.54M billion.
Cash & Marketable Securities€296.98M
Total Debt€48.44M
Net Cash€248.54M
Net Cash Per Share€0.60
Tangible Book Value Per Share€1.17
Margins
Gross margin is 97.23%, with operating margin of -153.08%, and net profit margin of -148.38%.
Gross Margin97.23%
Operating Margin-153.08%
Pretax Margin-149.16%
Net Profit Margin-148.38%
EBITDA Margin-135.52%
EBIT Margin-149.16%
Analyst Forecast
The average price target for Iovance Biotherapeutics is €7.09, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target€7.09
Price Target Upside109.15% Upside
Analyst ConsensusModerate Buy
Analyst Count9
Revenue Growth Forecast―
EPS Growth Forecast―